Clinical trials: Biphenotypic Acute Leukemia
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is…
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT04872790
- Testing
- Dasatinib, Methotrexate, Prednisone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
This phase I trial tests the safety, best dose, and effectiveness of revumenib given as maintenance therapy after standard hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia, acute myeloid…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
- Trial name
- NCT07498465
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Sponsor
- Children's Oncology Group
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
This phase I/II trial finds the best dose, side effects and how well giving venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in treating patients with acute…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm
- Trial name
- NCT04797767
- Testing
- Cladribine, Cytarabine, Mitoxantrone
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Washington
Acute Myeloid Leukemia (AML), MLL Rearrangement
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement.
- Trial name
- MLL-LSC (NCT07537738)
- Testing
- Detection of leukemia stem cell using multiparameter flow cytometry
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking University People's Hospital
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL.
- Trial name
- NCT07222579
- Testing
- Subcutaneous Blinatumomab
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment…
- Trial name
- HVA-MPAL (NCT07517510)
- Testing
- HVA
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Second Provincial General Hospital
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Inqovi Maintenance Therapy in Myeloid Neoplasms
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant.
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia
- Trial name
- NCT04980404
- Testing
- Inqovi
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia
- Trial name
- ACCESS (NCT04904588)
- Testing
- Busulfan, Fludarabine, Total-body irradiation
- Where
- 39 sites in United States
- Volunteers
- 300 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived…
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia
- Trial name
- NCT05292664
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew E. Place, MD
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
This phase II trial studies how well venetoclax and decitabine work in treating participants with acute myeloid leukemia that has come back or does not respond to treatment, or with high-risk myelodysplastic syndrome that has…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03404193
- Testing
- Decitabine, Laboratory Biomarker Analysis, Venetoclax
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Acute Leukemia, Myelodysplastic Syndromes
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT05170828
- Testing
- Cyclophosphamide, Fludarabine, Total Body Irradiation
- Sponsor
- Ossium Health, Inc.
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT04872478
- Testing
- MRX-2843
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT03674411
- Testing
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Leukemia of Ambiguous Lineage
Venetoclax Combined With Azactidine in the Treatment of ALAL
The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear.
- Trial name
- NCT05901974
- Testing
- Venetoclax, azactidine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sheng-Li Xue, MD
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
This phase Ib/II trial best dose, possible benefits and/or side effects of omacetaxine and venetoclax in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back (recurrent) or does not respond…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT04874194
- Testing
- Omacetaxine Mepesuccinate, Venetoclax
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center